Have any questions? 706-721-6582 or cts@augusta.edu
- EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP.
Clinical Trial
EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP.
This research study will look at the effectiveness of combining an experimental drug (EP0057) with a drug that is already approved for use in the treatment of ovarian cancer, Olaparib. This study will look at how ovarian cancer responds to the combination of EP0057 with Olaparib and the safety of giving the two drugs together.
Eligibility Criteria
- Subjects must be at least 18 years of age or older with a life expectancy greater than 3 months. Must have histologically confirmed diagnosis with high-grade serous ovarian cancer or high-grade endometriod ovarian cancer, including primary peritoneal or fallopian tube cancer Subjects with ovarian tumours of low malignant potential or low-grade may not participate.
RESEARCH. INNOVATION. DISCOVERY.